Phase 1 clinical trials on early-onset T1D showed that the administration of autologous expanded CD4+CD25+CD127− Tregs was associated with a reduced requirement of exogenous insulin and preservation of β-cell function, with this effect persisting for up to 1 year after infusion without severe adverse reactions (37, 38). This evidence concerns the gene INS and type 1 diabetes mellitus.